logo
Plus   Neg
Share
Email

Alexion Rejects Elliott Recommendation - Quick Facts

Alexion Pharmaceuticals, Inc. (ALXN) said the company has recently engaged in good faith with Elliott Advisors (UK) Limited, an affiliate of Elliott Management, to listen their recommendation that Alexion Pharma immediately launch a proactive sale process. The Board of Alexion Pharma unanimously decided that conducting a proactive sale process would not be in the best interest of shareholders.

Alexion Pharma said its Board considered, among other factors, that it is highly unusual for a biopharmaceutical company of its size to proactively launch a sale process.

Alexion also noted that it has not received any indications of interest to acquire the
company nor it has rejected any such inbound proposals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
Follow RTT
>